secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0001558370-25-003344
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MetaVia reports FY2024 net loss $27.6M; cash $16.0M funds into Q3 2025; DA-1726 data expected April
--------------------------------------------------------------------------------

- Net loss $27.6M ($3.56/share) vs $12.5M ($2.46/share) in 2023; R&D expenses rose to $21.6M from $9.2M.
- Cash $16.0M as of Dec 31, 2024 (down from $22.4M); expected to fund operations into Q3 2025.
- DA-1726: Top-line data from additional MAD Part 2 cohorts expected April 2025; proof-of-concept study planned Q4 2025.
- DA-1241: Phase 2a in MASH met primary endpoint (ALT reduction); full data at medical meeting 2025; FDA end-of-Phase 2 meeting H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000155837025003344/0001558370-25-003344-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000155837025003344/mtva-20250320x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-003344

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer